Literature DB >> 26552957

Chemotherapy and the recurrence score--results as expected?

Lajos Pusztai1.   

Abstract

Mesh：

Substances：

Year:  2015        PMID： 26552957     DOI： 10.1038/nrclinonc.2015.191

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  9 in total

1.  Association Between Use of the 21-Gene Recurrence Score Assay and Receipt of Chemotherapy Among Medicare Beneficiaries With Early-Stage Breast Cancer, 2005-2009.

Authors:  Michaela A Dinan; Xiaojuan Mi; Shelby D Reed; Gary H Lyman; Lesley H Curtis
Journal:  JAMA Oncol       Date:  2015-11       Impact factor: 31.777

2.  Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.

Authors:  Soonmyung Paik; Gong Tang; Steven Shak; Chungyeul Kim; Joffre Baker; Wanseop Kim; Maureen Cronin; Frederick L Baehner; Drew Watson; John Bryant; Joseph P Costantino; Charles E Geyer; D Lawrence Wickerham; Norman Wolmark
Journal:  J Clin Oncol       Date:  2006-05-23       Impact factor: 44.544

3.  A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.

Authors:  Soonmyung Paik; Steven Shak; Gong Tang; Chungyeul Kim; Joffre Baker; Maureen Cronin; Frederick L Baehner; Michael G Walker; Drew Watson; Taesung Park; William Hiller; Edwin R Fisher; D Lawrence Wickerham; John Bryant; Norman Wolmark
Journal:  N Engl J Med       Date:  2004-12-10       Impact factor: 91.245

4.  Utility of oncotype DX risk estimates in clinically intermediate risk hormone receptor-positive, HER2-normal, grade II, lymph node-negative breast cancers.

Authors:  Catherine M Kelly; Savitri Krishnamurthy; Giampaolo Bianchini; Jennifer K Litton; Ana M Gonzalez-Angulo; Gabriel N Hortobagyi; Lajos Pusztai
Journal:  Cancer       Date:  2010-11-15       Impact factor: 6.860

5.  Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial.

Authors:  Kathy S Albain; William E Barlow; Steven Shak; Gabriel N Hortobagyi; Robert B Livingston; I-Tien Yeh; Peter Ravdin; Roberto Bugarini; Frederick L Baehner; Nancy E Davidson; George W Sledge; Eric P Winer; Clifford Hudis; James N Ingle; Edith A Perez; Kathleen I Pritchard; Lois Shepherd; Julie R Gralow; Carl Yoshizawa; D Craig Allred; C Kent Osborne; Daniel F Hayes
Journal:  Lancet Oncol       Date:  2009-12-10       Impact factor: 41.316

6.  Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features.

Authors:  Lori J Goldstein; Robert Gray; Sunil Badve; Barrett H Childs; Carl Yoshizawa; Steve Rowley; Steven Shak; Frederick L Baehner; Peter M Ravdin; Nancy E Davidson; George W Sledge; Edith A Perez; Lawrence N Shulman; Silvana Martino; Joseph A Sparano
Journal:  J Clin Oncol       Date:  2008-08-04       Impact factor: 44.544

7.  Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection.

Authors:  Shelly S Lo; Patricia B Mumby; John Norton; Karen Rychlik; Jeffrey Smerage; Joseph Kash; Helen K Chew; Ellen R Gaynor; Daniel F Hayes; Andrew Epstein; Kathy S Albain
Journal:  J Clin Oncol       Date:  2010-01-11       Impact factor: 44.544

8.  Adoption of gene expression profile testing and association with use of chemotherapy among women with breast cancer.

Authors:  Michael J Hassett; Samuel M Silver; Melissa E Hughes; Douglas W Blayney; Stephen B Edge; James G Herman; Clifford A Hudis; P Kelly Marcom; Jane E Pettinga; David Share; Richard Theriault; Yu-Ning Wong; Jonathan L Vandergrift; Joyce C Niland; Jane C Weeks
Journal:  J Clin Oncol       Date:  2012-05-14       Impact factor: 44.544

9.  Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study.

Authors:  Mitch Dowsett; Jack Cuzick; Christopher Wale; John Forbes; Elizabeth A Mallon; Janine Salter; Emma Quinn; Anita Dunbier; Michael Baum; Aman Buzdar; Anthony Howell; Roberto Bugarini; Frederick L Baehner; Steven Shak
Journal:  J Clin Oncol       Date:  2010-03-08       Impact factor: 44.544
  9 in total
  2 in total

1.  The influence of 21-gene recurrence score assay on chemotherapy use in a population-based sample of breast cancer patients.

Authors:  Steven J Katz; Timothy P Hofer; Yun Li; Allison W Kurian; Irina Bondarenko; Jeremy M G Taylor; Reshma Jagsi; Kevin C Ward; Ann S Hamilton
Journal:  Breast Cancer Res Treat       Date:  2016-12-23       Impact factor: 4.624

2.  Chemotherapy decisions and patient experience with the recurrence score assay for early-stage breast cancer.

Authors:  Christopher R Friese; Yun Li; Irina Bondarenko; Timothy P Hofer; Kevin C Ward; Ann S Hamilton; Dennis Deapen; Allison W Kurian; Steven J Katz
Journal:  Cancer       Date:  2016-10-24       Impact factor: 6.921
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.